Ana de Vera joined Santhera in April 2022 as Head of Clinical Science. In this role, she was primarily responsible for overseeing clinical and science activities across the Santhera pipeline. Above all, this included developing the clinical regulatory dossier and leading the clinical strategy through the regulatory submission of vamorolone for the treatment of Duchenne muscular dystrophy (DMD). In January 2023, Ana was appointment as Global Program Lead for Vamorolone, overseeing all vamorolone development activities.

Ana joined Santhera after 20 years of experience in drug development. At Novartis, she led the development of multiple drugs, small molecules, monoclonal antibodies and gene therapies, from Phase 1 to Phase 3 and life cycle management, mainly in the immunology and neuroscience disease areas, including leading clinical teams through multiple successful regulatory submissions worldwide. Before joining the pharma industry in 2005, Ana was an investigator in clinical trials for multiple sclerosis, a member of central review committees and performed central reading of medical images at the University Hospital in Basel, Switzerland.

Ana holds a medical degree (MD) from the University of Oviedo, Asturias, Spain and from the University of Basel, Switzerland. She trained in Neurology at the University Hospital La Fe, Valencia, Spain and moved to work in multiple sclerosis research units first in Hospital Vall d’Hebron, Barcelona, and then in University Hospital Basel, Switzerland, where she continued practicing until 2012. Ana is a certified Neurologist in Spain and in Switzerland.